USD Fund I & II portfolio company Konruns Pharmaceutical has went passed the IPO vetting process on June 5th, 2018 and is expected to go public within Year 2018.
Greenwoods Investment now is holding 6.44% equity stake in Konruns. Given the great prospects ahead in Chinese healthcare industry and trust in drug R&D capability of Konruns, we look forward to generating superior return for our investors.
